| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.09.19 | Initial Results from MOUNTAINEER Trial Show Antitumor Activity of Tucatinib Combination in HER2-Positive Metastatic Colorectal Cancer | 656 | Business Wire | - First Presentation of Tucatinib With Trastuzumab in Metastatic Colorectal Cancer - - Findings Presented Today at the European Society for Medical Oncology (ESMO) 2019 Congress - Seattle... ► Artikel lesen | |
| 29.09.19 | ImmunoGen Presents Initial Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination with Carboplatin and Avastin at ESMO | 1.220 | Business Wire | FORWARD II Triplet Combination Demonstrates Encouraging Anti-Tumor Activity Preliminary Findings Support Ongoing Study in Platinum-Sensitive Patients ImmunoGen, Inc. (Nasdaq: IMGN), a leader... ► Artikel lesen | |
| 29.09.19 | NOXXON PRÄSENTIERT AKTUELLE KLINISCHE DATEN AUS DER NOX-A12 / KEYTRUDA- PHASE-1/2-KOMBINATIONSSTUDIE AUF DEM ESMO KONGRESS | 868 | Business Wire | WEBCAST-POSTERPRÄSENTATION: MORGEN, 30. SEPTEMBER UM 09:00 UHR MESZ NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), ein Biotechnologieunternehmen mit Fokus auf der Verbesserung... ► Artikel lesen | |
| 29.09.19 | NOXXON Presents Latest Clinical Data From Phase 1/2 NOX-A12 / Keytruda Combination Trial at the ESMO Congress | 899 | Business Wire | Webcast Poster Presentation Tomorrow, September 30, at 09.00 A.M. CEST
Regulatory News:
NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused... ► Artikel lesen | |
| 29.09.19 | ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO | 1.149 | Business Wire | FORWARD I Did Not Meet Primary Endpoint of Progression-Free Survival; Promising Efficacy Results Seen in Folate Receptor Alpha (FRa) High Patients Favorable Tolerability and Differentiated... ► Artikel lesen | |
| 29.09.19 | Clovis Oncology Highlights Rubraca (rucaparib) Updated Data from the Ongoing TRITON2 Clinical Trial in Patients with mCRPC and Exploratory and Integrated Analyses in Recurrent Ovarian Cancer at the ESMO Congress 2019 | 1.373 | Business Wire | 43.9% confirmed objective response rate (ORR) in 57 RECIST-evaluable patients with metastatic castration-resistant prostate cancer (mCRPC) and a BRCA1/2 mutation 52.0% confirmed prostate-specific... ► Artikel lesen | |
| 29.09.19 | Final Study Results Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress | 744 | Business Wire | Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced final results from the full endometrial cancer cohort of KEYNOTE-146/Study 111 evaluating KEYTRUDA,... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 439 |
| NVIDIA | 254 |
| DEUTSCHE BANK | 247 |
| BAYER | 215 |
| TESLA | 200 |
| RHEINMETALL | 190 |
| NEL | 180 |
| BYD | 178 |
| TUI | 163 |
| SUPER MICRO COMPUTER | 155 |
| BASF | 120 |
| MERCEDES-BENZ | 113 |
| AMAZON | 105 |
| RWE | 104 |
| VARTA | 102 |
| THYSSENKRUPP | 98 |
| MICROSOFT | 96 |
| PLUG POWER | 96 |
| AIXTRON SE | 94 |
| COMMERZBANK | 94 |
| VOLKSWAGEN | 93 |
| XIAOMI | 93 |
| DEUTSCHE LUFTHANSA | 89 |
| ALPHABET | 82 |
| DELIVERY HERO | 80 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
